Neurodegenerative diseases: A growing challenge

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 427-430

  Miksys, S L ^a   Tyndale, R F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; AGING; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; BRAIN; CALORIC INTAKE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; EDITORIAL; HERITABILITY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SITTING; SMOKING; TREATMENT PLANNING; DISEASE COURSE; HEALTH BEHAVIOR; NEURODEGENERATIVE DISEASES; PHYSIOLOGY;

AGING; BRAIN; DISEASE PROGRESSION; HEALTH BEHAVIOR; HUMANS; NEURODEGENERATIVE DISEASES; RISK FACTORS;

EID: 77957033804     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.198     Document Type: Editorial

References (13)

1. Bishop, N.A., Lu, T. & Yankner, B.A. Neural mechanisms of ageing and cognitive decline. Nature 464, 529-535 (2010).
2. Lee, Y. et al. Systematic review of health behavioral risks and cognitive health in older adults. Int. Psychogeriatr. 22, 174-187 (2010).
3. Dimitriadi, M. & Hart, A.C. Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans. Neurobiol. Dis. e-pub ahead of print, 19 May 2010.
4. Josephs, K.A. Dementia and the TAR DNA binding protein Clin. Pharmacol. Ther. 88, 555-558 (2010).
5. Carter, M.D., Simms, G.A. & Weaver, D.F. The development of new therapeutics for Alzheimers disease. Clin. Pharmacol. Ther. 88, 475-486 (2010).
6. Holtzman, J.L. Are we prepared to deal with the Alzheimers disease pandemic? Clin. Pharmacol. Ther. 88, 563-565 (2010).
7. Horowitz, M. & Greenamyre, J. Gene-environment interactions in Parkinsons disease: the importance of animal modeling. Clin. Pharmacol. Ther. 88, 467-474 (2010).
8. Rockwood, K. An individualized approach to tracking and treating Alzheimers disease. Clin. Pharmacol. Ther. 88, 446-449 (2010).
9. Mattson, M.P., Kapogiannis, D. & Greig, N.H. Tweaking energy metabolism to prevent and treat neurological disorders. Clin. Pharmacol. Ther. 88, 437-439 (2010).
10. Glass, C.K. et al. Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934 (2010).
11. Burke, K.A., Freeman, S.N., Imoisili, M.A. & Coté, T.R. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review. Clin. Pharmacol. Ther. 88, 449-453 (2010).
12. Hamani, C., Nobrega, J.N. & Lozano, J.M. Deep brain stimulation in clinical practice and in animal models. Clin. Pharmacol. Ther. 88, 559-562 (2010).
13. Larriviere, D. & Williams, M.A. Neuroenhancement: wisdom of the masses or "false phronesis"? Clin. Pharmacol. Ther. 88, 459-461 (2010).